CN104039822A - Glp-1衍生物 - Google Patents

Glp-1衍生物 Download PDF

Info

Publication number
CN104039822A
CN104039822A CN201280054416.0A CN201280054416A CN104039822A CN 104039822 A CN104039822 A CN 104039822A CN 201280054416 A CN201280054416 A CN 201280054416A CN 104039822 A CN104039822 A CN 104039822A
Authority
CN
China
Prior art keywords
amino
chemical formula
xaa
derivative
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280054416.0A
Other languages
English (en)
Chinese (zh)
Inventor
杰斯珀．刘
P．布洛奇
J．科福伊德
P．加里贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN201710403766.8A priority Critical patent/CN107266558A/zh
Publication of CN104039822A publication Critical patent/CN104039822A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201280054416.0A 2011-09-06 2012-09-06 Glp-1衍生物 Pending CN104039822A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710403766.8A CN107266558A (zh) 2011-09-06 2012-09-06 Glp‑1衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11180265.8 2011-09-06
EP11180265 2011-09-06
US201161532323P 2011-09-08 2011-09-08
US61/532,323 2011-09-08
PCT/EP2012/067364 WO2013037690A1 (en) 2011-09-06 2012-09-06 Glp-1 derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710403766.8A Division CN107266558A (zh) 2011-09-06 2012-09-06 Glp‑1衍生物

Publications (1)

Publication Number Publication Date
CN104039822A true CN104039822A (zh) 2014-09-10

Family

ID=47882647

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280054416.0A Pending CN104039822A (zh) 2011-09-06 2012-09-06 Glp-1衍生物
CN201710403766.8A Pending CN107266558A (zh) 2011-09-06 2012-09-06 Glp‑1衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710403766.8A Pending CN107266558A (zh) 2011-09-06 2012-09-06 Glp‑1衍生物

Country Status (6)

Country Link
US (2) US9758560B2 (https=)
EP (1) EP2753642B8 (https=)
JP (1) JP6126097B2 (https=)
CN (2) CN104039822A (https=)
ES (1) ES2626013T3 (https=)
WO (1) WO2013037690A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109248323A (zh) * 2017-07-14 2019-01-22 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2021239116A1 (zh) * 2020-05-29 2021-12-02 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
CN114621340A (zh) * 2022-03-11 2022-06-14 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物
CN114716533A (zh) * 2022-04-12 2022-07-08 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2846823B1 (en) * 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
SI3004155T1 (sl) * 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
ES2741507T3 (es) * 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
CA3022535A1 (en) 2016-04-28 2017-11-02 Novo Nordisk A/S Semaglutide in cardiovascular conditions
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
MX2020010505A (es) 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
CN113214381B (zh) * 2018-04-19 2024-01-19 杭州先为达生物科技股份有限公司 酰化的glp-1衍生物
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250110330A (ko) * 2022-11-21 2025-07-18 일라이 릴리 앤드 캄파니 Gip/glp1 이중 효능제의 제조 방법
WO2024158668A1 (en) * 2023-01-23 2024-08-02 CrossChem Limited Compounds for use in keratin treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232470A (zh) * 1996-08-30 1999-10-20 诺沃挪第克公司 Glp－1衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100671C (en) * 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
JPH08504209A (ja) * 1992-12-04 1996-05-07 アボツト・ラボラトリーズ ６位修飾デカペプチドｌｈｒｈ拮抗薬
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5663907A (en) * 1996-04-25 1997-09-02 Bright Microelectronics, Inc. Switch driver circuit for providing small sector sizes for negative gate erase flash EEPROMS using a standard twin-well CMOS process
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
EP1696962A2 (en) * 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
US20070135338A1 (en) 2004-03-31 2007-06-14 Karyn O'neil Human GLP-1 mimetibodies, compositions, methods and uses
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
JP6039569B2 (ja) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232470A (zh) * 1996-08-30 1999-10-20 诺沃挪第克公司 Glp－1衍生物

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109248323A (zh) * 2017-07-14 2019-01-22 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2021239116A1 (zh) * 2020-05-29 2021-12-02 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
US12509496B2 (en) 2020-05-29 2025-12-30 Shanghai Minwei Biotechnology Co., Ltd GLP-1/glucagon dual agonist fusion protein
CN114621340A (zh) * 2022-03-11 2022-06-14 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物
CN114621340B (zh) * 2022-03-11 2022-09-23 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物
CN114716533A (zh) * 2022-04-12 2022-07-08 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物

Also Published As

Publication number Publication date
EP2753642B8 (en) 2017-12-13
US9758560B2 (en) 2017-09-12
US10308700B2 (en) 2019-06-04
US20170145069A1 (en) 2017-05-25
EP2753642B1 (en) 2017-03-01
US20140303083A1 (en) 2014-10-09
JP6126097B2 (ja) 2017-05-10
JP2014529629A (ja) 2014-11-13
ES2626013T3 (es) 2017-07-21
CN107266558A (zh) 2017-10-20
WO2013037690A1 (en) 2013-03-21
EP2753642A1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
JP6126097B2 (ja) Ｇｌｐ−１誘導体
US11518795B2 (en) Double-acylated GLP-1 derivatives
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
CN102791731B (zh) Glp-1类似物和衍生物
JP6475233B2 (ja) Ｇｌｐ−１誘導体及びその使用
CN104411322B (zh) 双酰化glp‑1衍生物
CN108699126B (zh) Glp-1衍生物及其用途
JP6691125B2 (ja) Ｇｌｐ−１誘導体及びその使用
CN105451776B (zh) Glp-1衍生物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910

RJ01 Rejection of invention patent application after publication